Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients

Launched by UNIVERSITY HOSPITAL, GRENOBLE · Mar 21, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding how the body processes certain antibiotics called beta-lactams in patients who are on a life-support machine known as veno-arterial extracorporeal membrane oxygenation (VA-ECMO). This machine is often used for patients experiencing severe heart issues, such as cardiogenic shock or cardiac arrest. The goal of the study is to identify factors that may affect how well these antibiotics work in these critically ill patients, ensuring they receive the right amount to fight infections effectively.

To be eligible for this trial, participants must be patients currently undergoing VA-ECMO and starting a new antibiotic treatment with one of the beta-lactams being studied (like Piperacillin-Tazobactam, Cefepime, or Meropenem). They should also be expected to survive for more than 24 hours and must provide consent, or have someone they trust provide it for them. The study is not yet recruiting participants, but it aims to gather important information that could improve antibiotic treatment for patients on VA-ECMO.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing VA-ECMO
• • Patients requiering initiation of a novel antibiotic therapy with one of the studied beta-lactam (Piperacillin-Tazobactam, Cefepime, or Meropenem) while under VA-ECMO
• • With an expected survival exceeding 24 hours
• • Patient's or their trusted person's consent
• Exclusion Criteria:
• • Subject under administrative or judicial surveillance
• • Non-affiliation to social insurance
• • Pregnant or lactating patient
• • Antibiotic therapy of interest already initiated before VA-ECMO implantation
• • Contraindication to the use of beta-lactam
• • Administration modalities of beta-lactam not compliant with current recommendations
• • Subject in exclusion period from another study